In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
about
In Vitro Selection of Cancer Cell-Specific Molecular Recognition Elements from Amino Acid LibrariesA novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.Chicken scFvs with an Artificial Cysteine for Site-Directed ConjugationThe use of nanoparticles as a promising therapeutic approach in cancer immunotherapy.Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].Anti-Metastatic and Anti-Invasion Effects of a Specific Anti-MUC18 scFv Antibody on Breast Cancer Cells.Microbial platform technology for recombinant antibody fragment production: A review.Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy.Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells.Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one time injection in four dogs.Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models.The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.Refolding of Aggregation-Prone ScFv Antibody Fragments Assisted by Hydrophobically Modified Poly(sodium acrylate) Derivatives.Development of single-chain Fv of antibody to DNA as intracellular delivery vehicle
P2860
Q26782129-20784DF2-4352-4D5B-B74C-B40FAE555405Q33758660-200C1757-933C-4E07-BD10-F527D2B8380EQ36463396-3AAE19D6-71AF-4F43-AAA2-37E2B70C7A12Q38328927-6CB1CAC4-A6E5-412C-9849-344E35694E96Q38698179-8C01F672-7AE8-41FD-89ED-B7455B78ADC7Q38749875-47B2D4C3-22BE-4D01-BED5-D44C4B70F116Q38888751-AAD11BDF-C911-48A9-868D-23CC716116A1Q38904163-85F9B515-2E7C-4209-B012-61D0121D74F8Q38995018-09809366-CD03-48DA-BAFC-AEB61DB66657Q39062945-B5548B2A-F290-4913-A23A-E2C98FD3F4E3Q41033340-6514962D-C218-4FD1-84C0-3016DDB83A52Q44865598-454D2A2B-11B7-41BE-8024-2A316272319BQ47107902-B2E25AA4-70F1-4AEA-86D3-9738248773A8Q51352382-4EBB824D-18AD-4A0F-9E3E-1AC02D183203Q51557597-BA637578-3946-476A-AE3A-81B9CD881C44Q58277593-2B05592E-8B15-4FEF-A542-9070D8D1C811
P2860
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2013
@uk
name
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
@en
In Vivo Applications of Single Chain Fv
@nl
type
label
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
@en
In Vivo Applications of Single Chain Fv
@nl
prefLabel
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
@en
In Vivo Applications of Single Chain Fv
@nl
P2093
P2860
P356
P1476
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
@en
P2093
Nardos Tassew
Philippe Monnier
Robin Vigouroux
P2860
P304
P356
10.3390/ANTIB2020193
P577
2013-04-11T00:00:00Z